Hubert Schoemaker

Last updated • 4 min readFrom Wikipedia, The Free Encyclopedia
Hubert Schoemaker
Born(1950-03-23)March 23, 1950
Deventer, Netherlands
DiedJanuary 1, 2006(2006-01-01) (aged 55)
Paoli, Pennsylvania
NationalityDutch
Citizenship Dutch
Alma mater University of Notre Dame
Massachusetts Institute of Technology
Known for Remicade
SpouseAnn Postorino (1) Anne Faulkner Schoemaker (2) [1]
ChildrenMaureen, Katherine, Anne, and Hubert Matthew Schoemaker)
Scientific career
Fields immunology, biochemistry, business, biotechnology
Institutions Centocor
Corning
Neuronyx

Hubert Jacob Paul Schoemaker (March 23, 1950 – January 1, 2006) [2] was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies. In 1999 he founded Neuronyx, Inc., for the manufacture of stem cells and the development of stem-cell therapies. [3]

Contents

Early life and education

Schoemaker was born in Deventer, Netherlands. He attended St. Bernardus School in Deventer, and Canisius College, Nijmegen. In 1969 he moved to the United States to attend the University of Notre Dame, where he majored in chemistry, graduating in May 1972. Soon after he married Ann Postorino. [4]

He then earned a doctorate in biochemistry in 1975 from the Massachusetts Institute of Technology. Supervised by Paul Schimmel, his doctoral research was an investigation of the structure function relationships of transfer RNAs and their complexes. [4]

Career

After declining postdoctoral research positions with Stanley Cohen and Klaus Weber, Schoemaker chose to work as a research scientist in industry. His choice was influenced by the severe disabilities suffered by his first daughter, Maureen, who was born with lissencephaly and needed specialised care. This inspired Schoemaker to become involved in commercial biotechnology. [1]

In 1976 Schoemaker joined Corning Medical, a Boston-based division of Corning Glass Works. At Corning Schoemaker rapidly progressed from being a specialist in immunoassay development for diagnostics to heading research and development. Among his achievements at the company was devising effective diagnostic kit tests for thyroid disorders. [1]

In 1979 Schoemaker became involved in the founding of Centocor together with a former Corning Medical colleague Ted Allen and the bioentrepreneur Michael Wall with whom he had some dealings while at Corning. [1] Inspired by the work of Hilary Koprowski, who developed some of the earliest monoclonal antibodies against tumour antigens and influenza viral antigens, the objective of Centocor was to commercialise monoclonal antibodies for diagnostics and therapeutics. [5] In 1980 Schoemaker joined Centocor and soon after became its first chief executive officer. [1]

From the start Centocor decided to fill its product pipeline through partnerships with research institutions and marketing alliances. Central to this policy was Schoemaker's ability to network and the company's decision to design diagnostic kits so that were compatible with existing diagnostic systems. Under Schoemaker's leadership Centocor rapidly grew into a profitable diagnostic business. By 1985 the company had revenues of approximately $50 million. In part this success was built upon the swift approval the company won for two of its tests. The first was for gastrointestinal cancer test and the other was for hepatitis B. Between 1983 and 1986 Centocor introduced three other diagnostic tests to the market: one for ovarian cancer (the first diagnostic test available for the disease), one for breast cancer and one for colorectal cancer. [6]

Despite the company's success on the diagnostic front, Schoemaker was plunged in 1992 into efforts to save the company from bankruptcy when its first therapeutic, Centoxin, a drug designed to treat septic shock, failed to win FDA approval. [7] In part the crisis had come about as a result of the company's executives trying to go it alone in developing the drug. What saved the company was a return to the policy of collaboration. Learning from its mistakes with Centoxin, in December 1994 Centocor gained marketing approval for ReoPro, a monoclonal antibody drug for cardiovascular disease. The first therapeutic to ever receive simultaneous US and European approvals, and the second monoclonal antibody to ever win approval as a drug, ReoPro marked a milestone for both Centocor and for monoclonal antibodies therapeutics. ReoPro was to be followed in August 1998 by the approval of Centocor's Remicade, a drug to treat auto-immune disorders like Crohn's disease and rheumatoid arthritis. [8]

After selling Centocor to Johnson and Johnson in 1999, Schoemaker went on to form Neuronyx, Inc., a biotech company focused on developing cellular therapies. After Schoemaker died in 2006 the company was continued by his wife Anne Faulkner Schoemaker. Initial work focused on using stem cells taken from adult bone marrow to help regenerate heart tissue damaged during heart attacks. [9] Later the company turned direction to looking at the development of a treatment for incision wounds in women following breast cancer reconstruction surgery. The company later changed its name to Garnet BioTherapeutics. [10] Despite promising clinical results and raising more than $55 million in venture capital funding, the company was unable to continue. [11]

Death

Schoemaker was diagnosed in 1994 with a form of brain cancer, medulloblastoma. [1] He died on January 1, 2006, at age 55. [2]

Related Research Articles

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.

<span class="mw-page-title-main">Gregory Winter</span> English biochemist (born 1951)

Sir Gregory Paul Winter is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering, in Cambridge, England.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Johnson & Johnson Innovative Medicine is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

<span class="mw-page-title-main">Cetus Corporation</span> Pioneering biotech company in California, US

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California, in 1971, but conducted most of its operations in nearby Emeryville. Before merging with Chiron Corporation in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.

Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab was developed by Genentech under a partnership with Roche to treat heart attack, stroke, and traumatic shock.

Priliximab is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease and multiple sclerosis but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

<span class="mw-page-title-main">Kyowa Kirin</span>

Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.

<span class="mw-page-title-main">Nancy T. Chang</span> Biochemist

Nancy Tang Chang, née Tang Nanshan, is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug that focused on the allergy-related basis of asthma, Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million. Dr. Chang grew Tanox from an idea to a substantial publicly traded company, doing innovative science. Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

Afucosylated monoclonal antibodies are monoclonal antibodies engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose sugar units. When antibodies are afucosylated, antibody-dependent cellular cytotoxicity (ADCC) is increased.

<span class="mw-page-title-main">Optimer ligand</span>

Optimer ligands are short synthetic oligonucleotide molecules composed of DNA or RNA that bind to a specific target molecule. They are engineered to bind their target molecules with affinity typically in the low nanomolar range. Optimers can be used as antibody mimetics in a range of applications, and have been optimized to increase their stability, reduce their molecular weight, and offer increased scalability and consistency in manufacture compared to standard aptamer molecules.

Harvey J. Berger is an American physician-scientist, entrepreneur and biotechnology executive. He was the founder and chairman and chief executive officer of ARIAD Pharmaceuticals, Inc. for 25 years, starting in 1991 and became advisor to the board in 2016. He was also executive chairman at Medinol, Inc from 2017 to 2018. In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees.

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

References

  1. 1 2 3 4 5 6 "Dr. Hubert Schoemaker". What is Biotechnology?. Retrieved 9 November 2018.
  2. 1 2 Pollack, Andrew (January 13, 2006). "Hubert Schoemaker, a Biotech Pioneer, Dies at 55". The New York Times.
  3. ↑ Center for Oral History. "Hubert J.P. Schoemaker". Science History Institute .
  4. 1 2 Marks, Lara; Everson, Ted; Dionisio, Jen, eds. (9 July 1997). The Life of Hubert J. P. Schoemaker (1950–2006) An Oral History (PDF). Philadelphia, PA: Chemical Heritage Foundation.
  5. ↑ "Professor Hilary Koprowski". What is Biotechnology?. Retrieved 9 November 2018.
  6. ↑ Marks, L.V. (2009) "Collaboration - a competitor's tool: The story of Centocor, an entrepreneurial biotechnology company", Business History, 51(4): 529-46.
  7. ↑ Dionisio, Jennifer (2008). "A Will and a Way". Chemical Heritage Magazine. Chemical Heritage Foundation . Retrieved November 8, 2018.
  8. ↑ Marks, L. (2012) "The birth pangs of monoclonal antibody therapeutics", mAbs, 4 (3), 1-10.
  9. ↑ MORAN, SARAH E. (March 2, 2007). "Reducing tissue damage after a heart attack". Daily Local News. Retrieved 9 November 2018.
  10. ↑ "Company Overview of Garnet Biotherapeutics, Inc". Bloomberg. Retrieved 9 November 2018.
  11. ↑ "Venture-Backed Garnet BioTherapeutics, Inc. Files for Chapter 11 Bankruptcy". Seeking Alpha. December 30, 2010. Retrieved 9 November 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.